- Home
- CNK vs CELC Comparison
CNK vs CELC Comparison
Compare CNK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNK
- CELC
- Stock Information
- Founded
- CNK 1984
- CELC 2011
- Country
- CNK United States
- CELC United States
- Employees
- CNK N/A
- CELC N/A
- Industry
- CNK Movies/Entertainment
- CELC Medical Specialities
- Sector
- CNK Consumer Discretionary
- CELC Health Care
- Exchange
- CNK Nasdaq
- CELC Nasdaq
- Market Cap
- CNK 3.3B
- CELC 3.1B
- IPO Year
- CNK 2007
- CELC 2017
- Fundamental
- Price
- CNK $27.55
- CELC $100.31
- Analyst Decision
- CNK Strong Buy
- CELC Strong Buy
- Analyst Count
- CNK 10
- CELC 7
- Target Price
- CNK $35.30
- CELC $95.29
- AVG Volume (30 Days)
- CNK 3.1M
- CELC 882.6K
- Earning Date
- CNK 11-05-2025
- CELC 11-12-2025
- Dividend Yield
- CNK 1.17%
- CELC N/A
- EPS Growth
- CNK N/A
- CELC N/A
- EPS
- CNK 1.11
- CELC N/A
- Revenue
- CNK $3,153,000,000.00
- CELC N/A
- Revenue This Year
- CNK $7.03
- CELC N/A
- Revenue Next Year
- CNK $7.63
- CELC N/A
- P/E Ratio
- CNK $24.60
- CELC N/A
- Revenue Growth
- CNK 9.70
- CELC N/A
- 52 Week Low
- CNK $23.12
- CELC $7.58
- 52 Week High
- CNK $36.28
- CELC $103.06
- Technical
- Relative Strength Index (RSI)
- CNK 43.65
- CELC 77.69
- Support Level
- CNK $27.84
- CELC $92.10
- Resistance Level
- CNK $30.91
- CELC $103.06
- Average True Range (ATR)
- CNK 1.08
- CELC 5.49
- MACD
- CNK -0.31
- CELC 0.52
- Stochastic Oscillator
- CNK 8.27
- CELC 89.79
About CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.